South Australian experience with 177Lu-DOTATATE peptide receptor radionuclide therapy for neuroendocrine tumors provides real-world efficacy and safety data for this somatostatin-based treatment.
Key findingSouth Australian experience with 177Lu-DOTATATE peptide receptor radionuclide therapy for neuroendoc
What the researchers found
South Australian experience with 177Lu-DOTATATE peptide receptor radionuclide therapy for neuroendocrine tumors provides real-world efficacy and safety data for this somatostatin-based treatment.
Why it matters
Relevant to peptide therapeutics.
The numbers in context
189 patients treated over 11 years (2011-2022). Assessed for toxicity, radiological response, quality of life, and survival.
How the study worked
In publication.
Who was studied
189 patients with metastatic or advanced neuroendocrine tumors treated at an Australian hospital (2011-2022)
What this study cannot tell us
In publication.
How to read the evidence
Based on study design.
When this study was published
Published in 2025.
The bigger picture
Advances peptide therapeutic knowledge.
Questions still open
- Long-term implications?
- Comparison to evidence?
- Next research?
Common questions
What does this mean?
How reliable?
Read the original research
The South Australian 177Lu-DOTATATE peptide receptor radionuclide therapy service: an 11-year review of toxicity, health-related quality of life, and survival.
ESMO gastrointestinal oncology, 8, 100146
Citation
Altus, L M; Forster, J C; Mercurio, J; Kitchener, M; Corsini, N; Nenke, M; Price, T; Patel, D; Chew, R; Moffat, D; Unger, S; Cehic, G. (2025). The South Australian 177Lu-DOTATATE peptide receptor radionuclide therapy service: an 11-year review of toxicity, health-related quality of life, and survival.. ESMO gastrointestinal oncology, 8, 100146. https://doi.org/10.1016/j.esmogo.2025.100146